GMP IPO Watch
Aditya Birla Sun Life Pharma and Healthcare Fund
Direct Plan · GROWTH · Aditya Birla Sun Life Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | -1.71% | +0.76% | 239 of 255 |
| 1M | -4.74% | -1.72% | 247 of 254 |
| 3M | -4.83% | -2.69% | 197 of 251 |
| 6M | +11.27% | +3.12% | 45 of 251 |
| YTD | +12.02% | -0.08% | 32 of 255 |
| 1Y | +10.63% | +0.26% | 35 of 228 |
| 2Y | +3.86% | -0.63% | 56 of 185 |
| 3Y | +18.92% | +11.33% | 24 of 141 |
| 5Y | +12.90% | +9.09% | 36 of 102 |
| 7Y | +20.77% | +14.65% | 21 of 83 |
| INCEPTION | +20.09% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +5.49% | +39.64% | -13.11% | 70% | 29% |
| 6M | +11.10% | +64.25% | -15.95% | 73% | 31% |
| 1Y | +23.03% | +72.90% | -15.55% | 80% | 37% |
| 2Y | +20.41% | +44.99% | -2.31% | 97% | 45% |
| 3Y | +19.65% | +27.80% | +12.13% | 100% | 47% |
| 5Y | +19.67% | +29.27% | +12.91% | 100% | 47% |
| 7Y | +21.75% | +22.34% | +20.78% | 100% | 49% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity97.93%
- Debt0.00%
- Cash2.07%
- Other0.00%
Market Cap Split
- Large Cap32.95%
- Mid Cap31.71%
- Small Cap33.28%
- Others2.06%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 39.59 | 42.02 |
| P/B | 6.02 | 6.30 |
| Price / Sales | 5.79 | 6.07 |
| Price / Cash Flow | 30.23 | 31.31 |
| Dividend Yield (%) | 0.82 | 0.60 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 9.28% | -0.29% |
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 8.61% | -0.58% |
| Apollo Hospitals | Equity | 6.44% | -0.41% |
| Cipla | Pharmaceuticals & Biotechnology | 6.38% | +1.22% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 4.52% | -0.01% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 4.49% | +0.29% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 4.35% | +0.13% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 3.62% | +0.21% |
| Dr. Lal Path Labs | Equity | 3.51% | +1.41% |
| Abbott | Pharmaceuticals & Biotechnology | 3.26% | +0.23% |
| Emcure Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.21% | +0.22% |
| Lupin | Pharmaceuticals & Biotechnology | 2.94% | -0.16% |
| TREPS | Reverse Repo / TREPS | 2.92% | — |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 2.71% | +0.00% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 2.70% | +0.07% |
View all 41 holdings
| Fortis Healthcare | Equity | 2.42% | -0.37% |
| Corona Remedies | Pharmaceuticals & Biotechnology | 2.27% | +0.10% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 2.24% | +0.01% |
| Procter & Gamble Health | Pharmaceuticals & Biotechnology | 1.82% | -0.02% |
| Thyrocare Technologies | Equity | 1.76% | -0.18% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 1.68% | -0.01% |
| Jupiter Life Line Hospital | Equity | 1.55% | -0.21% |
| Metropolis Healthcare | Equity | 1.48% | -0.07% |
| Biocon | Pharmaceuticals & Biotechnology | 1.45% | +0.26% |
| Shilpa Medicare | Pharmaceuticals & Biotechnology | 1.43% | +0.16% |
| Piramal Pharma | Pharmaceuticals & Biotechnology | 1.22% | -0.02% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 1.13% | +0.09% |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 1.13% | -0.02% |
| Sanofi Consumer Healthcare | Pharmaceuticals & Biotechnology | 1.11% | -0.07% |
| Suraksha Diagnostic | Equity | 1.10% | +0.07% |
| Manipal Health Enterprises | Equity | 1.07% | -0.05% |
| Vijaya Diagnostic Centre | Equity | 1.04% | -0.04% |
| Pfizer | Pharmaceuticals & Biotechnology | 1.01% | -0.18% |
| Natco Pharma | Pharmaceuticals & Biotechnology | 0.92% | +0.00% |
| GlaxoSmithKline Pharmaceuticals | Pharmaceuticals & Biotechnology | 0.83% | -0.07% |
| Medi Assist Healthcare | Insurance | 0.73% | -0.05% |
| Vinati Organics | Chemicals & Petrochemicals | 0.69% | -0.08% |
| Syngene International | Equity | 0.64% | -0.05% |
| Max Healthcare Institute | Equity | 0.60% | -0.06% |
| Jubilant Pharmova | Pharmaceuticals & Biotechnology | 0.60% | +0.10% |
| Net Receivable / Payable | Net Current Assets | -0.85% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 15.85 | 14.95 | High Volatility |
| 3Y | 15.58 | 16.41 | Low Volatility |
| 5Y | 15.36 | 15.61 | Low Volatility |
What is this?
Risk as measured by standard deviation is a statistical measure that quantifies the amount of variation or dispersion in a set of data points relative to its mean (average).
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.03 | 0.80 | Good Risk Adjusted Returns |
| 3Y | 0.87 | 0.81 | Good Risk Adjusted Returns |
| 5Y | 0.56 | 0.54 | Good Risk Adjusted Returns |
What is this?
Higher the value means that fund has been able to give better returns for the amount of risk taken. It helps investors understand the return of an investment compared to its risk, showing whether the returns are due to intelligent investing or simply taking on excess risk. It is calculated by subtracting the risk-free return, defined as an Indian Government Bond, from the fund's returns, and then dividing by the standard deviation of returns.
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.85 | 1.40 | Good Risk Adjusted Returns |
| 3Y | 1.54 | 1.37 | Good Risk Adjusted Returns |
| 5Y | 0.93 | 0.87 | Good Risk Adjusted Returns |
What is this?
The Sortino Ratio is a financial metric used to measure the risk-adjusted return of an investment. It's a modification of the Sharpe Ratio but with a key difference; it only considers downside risk (the risk of negative returns), rather than total volatility. This means it focuses on how well an investment performs relative to the volatility that leads to losses, ignoring the volatility that results in gains. The idea is that investors are primarily concerned with minimizing losses, and positive volatility is generally seen as a good thing.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.80 | 0.96 | Good Risk Adjusted Returns |
| 3Y | 0.91 | 0.96 | Good Risk Adjusted Returns |
| 5Y | 0.93 | 0.94 | Good Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+99.60% | +55.10% | — | +28.54% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+27.34% | +22.09% | +9.79% | +8.89% |
|
Franklin Asian Equity Fund
Regular Plan · IDCW
|
+22.02% | +19.22% | +4.06% | +3.99% |
|
Motilal Oswal Active Momentum Fund
Direct Plan · Growth
|
+20.32% | — | — | +26.30% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+19.95% | +28.44% | — | +28.32% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+19.81% | +17.63% | +11.76% | +15.66% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+18.64% | — | — | +18.53% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+18.43% | — | — | +10.20% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.39% | +33.78% | — | +37.35% |
|
Nippon India US Equity Opportunities Fund
Regular Plan · Growth Option
|
+16.88% | +19.53% | +10.77% | +14.16% |
More From Aditya Birla Sun Life AMC Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Aditya Birla Sun Life US Equity Passive FOF
Direct Plan · GROWTH
|
+29.28% | +30.96% | — | +18.61% |
|
Aditya Birla Sun Life Silver ETF FOF
Direct Plan · GROWTH
|
+26.01% | +41.30% | — | +28.26% |
| Aditya Birla Sun Life Silver ETF | +23.78% | +42.41% | — | +29.22% |
|
Aditya Birla Sun Life Global Excellence Equity Fund Of Fund
Direct plan · IDCW
|
+20.43% | +22.06% | +13.99% | +9.38% |
|
Aditya Birla Sun Life International Equity Fund
Direct Plan · GROWTH
|
+17.20% | +22.41% | +12.20% | +12.00% |
|
Aditya Birla Sun Life Manufacturing Equity Fund
Direct Plan · GROWTH
|
+15.43% | +19.22% | +13.26% | +13.06% |
|
Aditya Birla Sun Life Global Emerging Opportunities Fund
Direct Plan · IDCW
|
+15.01% | +19.20% | +9.75% | +7.40% |
| Aditya Birla Sun Life Gold ETF | +14.33% | +34.00% | +23.79% | +11.99% |
|
Aditya Birla Sun Life Gold Fund
Direct Plan · GROWTH
|
+14.27% | +34.05% | +23.75% | +10.83% |
|
Aditya Birla Sun Life Nifty India Defence Index Fund
Direct Plan · IDCW Payout
|
+13.73% | — | — | +14.30% |
About This Scheme
Investment Objective
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
Stated Asset Allocation
Under normal circumstances, the asset allocation of the Scheme will be as follows: Equities & Equity related instruments of companies in the Pharma, Healthcare and Allied sectors - 80%-100% Other Equities & Equity related instruments- 0%-20% Units issued by InvITs - 0%-10% Liquid* and Money market instruments - 0%-20% Units of Mutual Funds^ - 0%-20% *As defined by SEBI. ^Overnight, Liquid and Money Market Funds.
Exit Load
For redemption/switch-out of units on or before 30 days from the date of allotment: 1.00% of applicable NAV. For redemption/switch-out of units after 30 days from the date of allotment: Nil
Fund Managers
Mr. Dhaval Shah
Primary
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.